International Journal of Clinical Case Reports, 2025, Vol.15, No.3, 139-147 http://medscipublisher.com/index.php/ijccr 139 Review Article Open Access Study on the Application of Targeted Therapy Combined with Chemotherapy in Cervical Cancer Patients Liting Wang Hainan Institute of Biotechnology, Haikou, 570206, Hainan, China Corresponding email: liting.wang@hibio.org International Journal of Clinical Case Reports 2025, Vol.15, No.3 doi: 10.5376/ijccr.2025.15.0015 Received: 29 Apr., 2025 Accepted: 03 Jun., 2025 Published: 29 Jun., 2025 Copyright © 2025 Wang, This is an open access article published under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Preferred citation for this article: Wang L.T., 2025, Study on the application of targeted therapy combined with chemotherapy in cervical cancer patients, International Journal of Clinical Case Reports, 15(3): 139-147 (doi: 10.5376/ijccr.2025.15.0015) Abstract This study talks about using targeted therapy and chemotherapy together to treat cervical cancer. It mainly looks at two things: how well this treatment works and if it’s safe. This is very important for people whose cancer has come back or has spread. The results are encouraging. When patients take drugs like bevacizumab (which stops new blood vessels from forming) and pembrolizumab (which helps the body’s defense system), they often live longer. Their cancer also grows more slowly. This treatment works well because it attacks the cancer in two ways. It works on the area around the tumor and helps the body fight the cancer. This makes it harder for the cancer to survive. In general, this mix of drugs works better than using only one. The study also gives useful ideas on how to make treatment plans that match each patient. It could help more doctors use this method in real hospitals later on. Keywords Cervical cancer; HPV; Targeted therapy; Chemotherapy; Combined therapy; Immune checkpoint inhibitors 1 Introduction Cervical cancer is a big health problem for women around the world. It leads to many illnesses and deaths, mainly in less wealthy countries. In 2020, around 604 000 women got this disease, and about 342 000 died from it. It was the fourth most common cancer among women (Xi et al., 2023). The main cause of cervical cancer is infection with human papillomavirus (HPV). Types 16 and 18 are the most dangerous. They cause about 70% of all cases. HPV vaccines and screening have helped a lot in some places. But in many low- and middle-income countries, people still can’t get them. So the cancer is still very common there (Arbyn et al., 2019). How doctors treat cervical cancer depends on when they find it. If the cancer is found early, surgery is often used. This can mean removing the uterus or just a small part, like in conization. If the cancer is still in the pelvic area but has grown, doctors usually use chemo and radiation together. This often includes cisplatin and two types of radiation. This combo has helped patients live longer (Tiwari et al., 2018). When the cancer spreads or comes back again, chemotherapy is the main way to treat it. Doctors often use cisplatin or carboplatin, and sometimes add paclitaxel. But in the later stages, these drugs may not work very well. They can also bring strong side effects, like hurting the kidneys or lowering blood cells. After a while, many patients no longer respond to the medicine, and the cancer keeps getting worse (Zhang et al., 2024). Even with new drugs, people with late-stage or returning cervical cancer often don’t do well. Most live less than five years after they are diagnosed. Usual treatments don’t stop the cancer for long. The side effects can also make people feel worse (Wu et al., 2024). So, better treatments are still needed. Targeted therapy is a newer kind of cancer treatment. It tries to block special signals that cancer cells need to grow. One common drug is bevacizumab. It stops a protein called VEGF that helps tumors grow new blood vessels. Some studies found that when bevacizumab is used with chemo, patients live longer and the cancer grows slower (Arbyn et al., 2019). But using this drug alone doesn’t always work. After a while, the cancer may find a way around it.
RkJQdWJsaXNoZXIy MjQ4ODYzNA==